Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b/2a, Double-blinded, Placebo-controlled, Multiple Doses, 2 Step-up Study Evaluating the Safety, Tolerability, PK/PD and Efficacy of Systemic NS101 in Healthy Volunteers and SSNHL Patients

Next Previous
Trial Profile

A Phase 1b/2a, Double-blinded, Placebo-controlled, Multiple Doses, 2 Step-up Study Evaluating the Safety, Tolerability, PK/PD and Efficacy of Systemic NS101 in Healthy Volunteers and SSNHL Patients

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 02 Sep 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs NS 101 Neuracle Science (Primary)
  • Indications Sensorineural hearing loss
  • Focus Adverse reactions
  • Sponsors Neuracle Science

Most Recent Events

  • 13 Aug 2025 Planned number of patients changed from 118 to 138.
  • 13 Aug 2025 Planned End Date changed from 19 Jun 2025 to 31 Jan 2027.
  • 13 Aug 2025 Planned primary completion date changed from 19 Jun 2025 to 31 May 2026.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top